Cargando…
Tumor necrosis factor-α blockade in ankylosing spondylitis: a potent but expensive anti-inflammatory treatment or true disease modification?
Blocking tumor necrosis factor-α either with monoclonal antibodies or with soluble receptor constructs has been proven to be effective with an acceptable safety profile in patients with rheumatoid arthritis, and more recently also in the diseases belonging to the spondyloarthropathy concept. Neverth...
| Autores principales: | , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2005
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1174966/ https://www.ncbi.nlm.nih.gov/pubmed/15899063 http://dx.doi.org/10.1186/ar1742 |